Clinical trials recruiting in Fresno, California

Phase breakdown

Conditions recruiting in Fresno, California

Recruiting trials in Fresno, California

• A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
  NCT07165028 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
  NCT06680830 · Phase: Phase 2 · Ages: 40 Years to 80 Years · Sex: All (male and female)
• A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
  NCT06906562 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
  NCT06318169 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female)
• A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
  NCT06433752 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
  NCT06920043 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
  NCT06810505 · Phase: Phase 3 · Ages: 12 Years to 17 Years · Sex: All (male and female)
• A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults
  NCT06625060 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female)
• A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
  NCT07105111 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
  NCT06419374 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
  NCT06937229 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female)
• ACP-204 in Adults With Alzheimer's Disease Psychosis
  NCT06159673 · Phase: Phase 2, Phase 3 · Ages: 55 Years to 95 Years · Sex: All (male and female)
• Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
  NCT06616584 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH
  NCT06129240 · Phase: Not specified · Ages: 18 Years to 80 Years · Sex: All (male and female)
• Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
  NCT06235697 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male
• Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
  NCT03907046 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
  NCT06418204 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
  NCT07195695 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
  NCT06096844 · Phase: Phase 3 · Ages: 70 Years and older · Sex: All (male and female)
• Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
  NCT05174169 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
  NCT05485961 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
  NCT05297734 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
  NCT05642572 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
  NCT04852887 · Phase: Phase 3 · Ages: 50 Years to 70 Years · Sex: All (male and female)
• Distance-Based Exercise to Preserve Function and Prevent Disability
  NCT07059884 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• E-Mindfulness Approaches for Living After Breast Cancer
  NCT06748222 · Phase: Phase 3 · Ages: 18 Years to 50 Years · Sex: All (male and female)
• Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy
  NCT06712407 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female)
• Enzalutamide Implants (Enolen) in Patients With Prostate Cancer
  NCT06257693 · Phase: Phase 1 · Ages: 21 Years and older · Sex: Male
• Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
  NCT05879926 · Phase: Phase 3 · Ages: 18 Years to 60 Years · Sex: Female
• Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
  NCT06498635 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
  NCT06632444 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
  NCT04743141 · Phase: Phase 3 · Ages: 6 Years to 17 Years · Sex: All (male and female)
• Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
  NCT03851445 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type
  NCT05397639 · Phase: Phase 3 · Ages: 50 Years to 90 Years · Sex: All (male and female)
• Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T
  NCT06134232 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male
• Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
  NCT06274801 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
  NCT04181060 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Persona Revision Knee System Outcomes
  NCT04821154 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• Randomized Study in Children and Adolescents With Migraine: Acute Treatment
  NCT04649242 · Phase: Phase 3 · Ages: 6 Years to 17 Years · Sex: All (male and female)
• Rising Tide - Amniotic Tissue(s) Treatments for Chronic Diabetic Foot Ulcers
  NCT06681428 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
  NCT03418961 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Safety and Feasibility of Umbilical Cord Wharton's Jelly Allograft Injections for Knee Osteoarthritis
  NCT06608134 · Phase: Early Phase 1 · Ages: 30 Years and older · Sex: All (male and female)
• ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
  NCT06876714 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
  NCT03678025 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male
• Study of EVO756 in Adults With Migraine
  NCT07616128 · Phase: Phase 2 · Ages: 18 Years to 64 Years · Sex: All (male and female)
• Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
  NCT05125302 · Phase: Phase 3 · Ages: 6 Years to 17 Years · Sex: All (male and female)
• Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
  NCT05946213 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male
• Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
  NCT06931340 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male
• Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
  NCT04267848 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
  NCT06975865 · Phase: Phase 3 · Ages: 10 Years to 65 Years · Sex: All (male and female)

Common questions

How many clinical trials are recruiting in Fresno, California?

50 recruiting trials have at least one study site in Fresno, California.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.